UCB Looks To Its Next Wave Of Innovative Products
Executive Summary
Early clinical-stage products for neurological and autoimmune diseases are progressing through the European biopharma's pipeline.
You may also be interested in...
UCB Buoyed By More Positive Bimekizumab Data
The Belgian group has a lot of catching up to do with Cosentyx and Taltz already well established but is confident bimekizumab’s mechanism of action, which neutralizes both IL-17A and IL-17F cytokines, offers an advantage over those two blockbusters.
UCB's Head of Corporate Strategy On Deals, Divestments And Sector-Wide Challenges
UCB's recently appointed head of corporate strategy and business development Alexander Moscho, who joined the company in October 2017, talks to Scrip about UCB's future growth, internal R&D pipeline and potential for significant deal-making in 2018.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.